
Restore Medical secures $23M Series B to push forward novel heart failure therapy
The new funding will allow the Israeli startup to complete an ongoing feasibility study in Europe, where early results have shown what the company describes as encouraging long-term safety and efficacy data.
Restore Medical, an Israeli clinical-stage medical technology company, has closed a $23 million Series B round to advance its minimally invasive device for treating heart failure, a condition that remains one of the world’s leading causes of death and hospitalization despite decades of pharmaceutical innovation.
Full list of Israeli high-tech funding rounds in 2025
The new financing, announced on Monday, is co-led by Pitango HealthTech, one of Israel’s largest healthcare-focused venture capital funds, and an undisclosed global strategic healthcare partner. The round also includes the European Innovation Council (EIC) Fund and continued backing from Peregrine Ventures, which has supported the company since its earliest days.
The fresh capital will allow Restore Medical to complete an ongoing feasibility study in Europe, where early results have shown what the company describes as encouraging long-term safety and efficacy data. The funding will also support a planned U.S.-based clinical trial, following the FDA’s decision in 2024 to grant the company’s device a Breakthrough Device Designation, an accelerated regulatory pathway for technologies with the potential to address unmet medical needs.
Heart failure affects an estimated 64 million people globally and remains a stubborn challenge for healthcare systems, especially for patients with Heart Failure with reduced Ejection Fraction (HFrEF). While drug treatments have extended survival and improved quality of life for many, a large proportion of patients remain symptomatic, with few viable options once standard therapies lose their effectiveness. Device-based solutions, including implantable defibrillators and ventricular assist devices, exist but often come with significant surgical risks or are reserved for the most advanced cases.
Related articles:
Restore Medical’s technology aims to bridge this gap with a transcatheter approach that does not require open-heart surgery. Early trial data has indicated improvements in cardiac remodeling, the process by which the heart’s shape and function can worsen over time in heart failure patients, as well as better hemodynamic performance and enhanced patient capacity.
The company was co-founded by CTO Stephen Bellomo, Dr. Elchanan Bruckheimer (Medical Director), and Aaron Feldman, and is led by CEO Gilad Marom. It began operations within Peregrine Ventures’ Incentive Incubator.